Sep. 16 at 5:17 PM
Spartan Capital Securities and B2i Digital are pleased to announce that Lixte Biotechnology Holdings, Inc. (Nasdaq:
$LIXT) will be a presenting company at the upcoming Spartan Capital Securities, LLC Investor Conference on November 3rd, 2025, in New York.
The Spartan Capital Investor Conference 2025 is a B2i Digital Featured Conference. Now in its second year, the conference brings together public company executive teams, institutional investors, and thought leaders from across the U.S. capital markets for strategic networking and information exchange. Taking place at the Marriott Marquis Hotel in New York, this premier event will welcome 500+ institutional and high-net-worth investors and feature presentations from 60 public and private growth companies across technology, healthcare, consumer, and other high-opportunity sectors. Attendees can expect main-stage presentations, curated one-on-one meetings, and extensive networking opportunities that connect innovative companies with sophisticated capital.
Investors can register to attend: https://www.meetmax.com/sched/event_125183/investor_reg_new.html?attendee_role_id=SPARTAN_INVESTOR_ATT.
Event details and registration are available at https://b2idigital.com/spartan-capital-investor-conference-2025.
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) is a clinical-stage pharmaceutical company developing a new class of oncology treatments and cancer therapies called PP2A inhibitors. In recent years, the field of cancer treatment has undergone remarkable advancement with the introduction of immunotherapy. This approach has revolutionized the landscape of cancer care. Both chemotherapy, and immunotherapy are treatment modalities that offer broad applicability to many types and stages of cancer, with the potential to benefit a wide range of patients. Our lead molecule LB-100 has shown remarkable synergy with chemotherapy and immunotherapy in a range of pre-clinical models.
The company is led by CEO Geordan Pursglove, an accomplished executive with 10+ years in M&A and capital markets; CSO Bastiaan (Bas) van der Baan, a biotechnology executive with 20+ years in precision oncology; CFO Peter Stazzone, a seasoned finance professional and CPA with 25 years of expertise; and supported by a Scientific Advisory Committee including Prof. Rene Bernards, Stephen Forman MD, and Yun Yen MD PhD FACP.
B2i Digital is working closely with the Spartan Capital team, including John D. Lowry (CEO), Kim Monchik (CAO), Stephen Faucetta (Managing Director), and Julia Voss (Executive Assistant), to enhance each presenter’s reach through in-depth digital profiles and targeted outreach.
Learn more about Lixte Biotechnology Holdings, Inc. at https://ir.lixte.com/